Urovant Sciences

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Urovant Sciences sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 8 completed top decile by trial count

Urovant Sciences: 10 sponsored US clinical trials, 1 recruiting.

Urovant Sciences sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 4 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neurogenic Detrusor Overactivity, with 1 trials.

Top-decile sponsor footprint

Urovant Sciences ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC

NCT05491525
COMPLETED

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

NCT05067478
COMPLETED Phase 2

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

NCT04211831
COMPLETED Phase 3

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

NCT04103450
COMPLETED Phase 3

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080
COMPLETED Phase 2

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

NCT03806127
COMPLETED Phase 3

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

NCT03583372
COMPLETED Phase 3

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281
COMPLETED Phase 1

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

NCT01870037
TERMINATED Phase 1

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

NCT00495053

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 4

Therapeutic Areas

Neurogenic Detrusor Overactivity 1

What is open in the Urovant Sciences pipeline

1 recruiting of 10 indexed (10% open); 8 completed (80%).

Phase mix: 4 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Neurogenic Detrusor Overactivity (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Urovant Sciences: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Urovant Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Urovant SciencesAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Urovant Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Urovant Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Urovant Sciences page

10 registered trials is a research-attention snapshot, not an endorsement of Urovant Sciences or any single study.

  • 1 of Urovant Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Neurogenic Detrusor Overactivity is the condition Urovant Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neurogenic Detrusor Overactivity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Urovant Sciences pipeline card: 10 registered trials from official public datasets.Report a data error.